The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
16-Nov-23
Pending
$400 million
Target:
Sonoma-Cutrer Vineyards (Brown-Forman)
Acquiror:
The Duckhorn Portfolio
Advising Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
14-Nov-23
Undisclosed
Target:
Minerals and Royalties Interest
Acquiror:
Undisclosed
Advised a company on the sale of its minerals and royalties interests in the Appalachian Basin
26-Oct-23
~$755 million
Target:
Innergex France
Acquiror:
Crédit Agricole Assurances
Advised Crédit Agricole Assurances, France’s largest insurance Group, in relation to its long-term partnership agreement with Innergex Renewable Energy Inc. (TSX: INE) and the acquisition of a 30% minority stake in Innergex France, the French operating and development activities of Innergex Renewable Energy Inc, for an enterprise value of €715m (@ 100%).
19-Oct-23
~A$1.3 billion (AUD value)
Target:
Liontown Resources Limited
Advised Australian-based lithium company Liontown Resources Limited on its A$855m debt financing package and up to A$421m equity raising to fund the Kathleen Valley Lithium Project
04-Oct-23
Pending
$530 million
Target:
FW Murphy Production Controls
Acquiror:
Dover Corporation
Advising Genisys Controls LLC on the sale of FW Murphy Production Controls, an instrumentation company that provides advanced monitoring and protection solutions used in sophisticated process applications, to Dover Corporation, a diversified global manufacturer and solutions provider
04-Oct-23
$610 million
Target:
Lucky Bucks, LLC
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process.
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
19-Sep-23
$60 million
Target:
Williams Industrial Services Group
Acquiror:
EnergySolutions
Advised Williams Industrial Services Group, (NYSE: WLMS), a maintenance & construction services provider to the commercial nuclear power and heavy industry markets, on its Section 363 sale to EnergySolutions, a global provider of nuclear, energy and industrial services
18-Sep-23
Pending
Undisclosed
Target:
Central nervous system (CNS) portfolio from Sanofi
Acquiror:
Pharmanovia
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company.
04-Sep-23
Pending
$6.6 billion AUD
Target:
Liontown Resources Limited
Acquiror:
Albemarle Corporation
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation.
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
21-Jul-23
Undisclosed
Target:
Synfonium / Qwant / Shadow
Acquiror:
Caisse des Dépôts et Consignations (CDC) / Banque des Territoires
Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
14-Jul-23
$333 million
Target:
Canopy Growth Corporation
Acquiror:
N/A
Advised Canopy Growth, a leading diversified cannabis company, on a series of agreements, including privately negotiated redemption agreements with certain holders of its unsecured senior notes due July 15, 2023 and agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021, that will have the overall effect of deleveraging the Company’s balance sheet by ~C$437mm over time
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
07-Jul-23
Pending
$439 million
Target:
Australian Unity Diversified Property Fund
Acquiror:
Cromwell Direct Property Fund
Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund
26-Jun-23
Pending
$583 million
Target:
Mandala Multifinance
Acquiror:
MUFG and Adira Finance
Advising JG Motor and certain other shareholders on the sale of Mandala Multifinance, a leading consumer finance company listed in Indonesia to MUFG and Adira Finance
21-Jun-23
Pending
Undisclosed
Target:
Jacobson/Gershwind Family
Acquiror:
MSC Industrial Direct Co.
Advising the Jacobson/Gershwind Family in connection with the elimination of MSC Industrial's Class B common stock, which included the conversion of each share of Class B common stock into the right to receive 1.225 shares of Class A common stock
20-Jun-23
Pending
$595 million
Target:
Lookers Plc
Acquiror:
Alpha Auto Group
Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company